Melphalan-mobilized blood stem cell components contain minimal clonotypic myeloma cell contamination

Blood

Volumn 102, Issue 2, 2003, Pages 477-479

  Zhou, Ping ^b   Zhang, Yana ^b   Martinez, Carmen ^b   Kalakonda, Nagesh ^b   Nimer, Stephen D ^b   Comenzo, Raymond L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN; MELPHALAN;

ADULT; AGED; ARTICLE; CELL FUNCTION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INTERMETHOD COMPARISON; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELIABILITY; STEM CELL MOBILIZATION;

EID: 0038156367     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-12-3674     Document Type: Article

References (25)

1. The Myeloma Trialists' Collaborative Group. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: overview of 6,633 patients from 27 randomized trials. J Clin Oncol. 1998;16:3832-3842.
2. Bergsagel DE. Chemotherapy of myeloma. In: Malpas JS, Bergsagel DE, Kyle RA, Anderson KC, eds. Myeloma Biology and Management. 2nd ed. New York, NY: Oxford University Press; 1998:269-302.
3. Attal M, Harousseau JL, Stoppa AM, et al. Autologous bone marrow transplantation versus conventional chemotherapy in multiple myeloma: a prospective randomized trial. N Engl J Med. 1996;335:91-97.
4. Kröger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood. 2002;100:755-760.
5. Corradini P, Voena C, Astolfi M, et al: High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood. 1995;85:1596-1602.
6. Lemoli R, Fortuna A, Motta MR, et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of endched CD34 cells to remove circulating tumor cells. Blood. 1996;87:1625-1634.
7. Gertz MA, Witzig TE, Pineda AA, Greipp PR, Kyle RA, Litzow MR. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation. Bone Marrow Transplant. 1997;19:337-342.
8. Vescio R, Schiller G, Stewart AK, et al. Multicenter phase III trial to evaluate CD34(+) selected versus unselected autologous peripheral blood progenitor cell transplantation in multiple myeloma. Blood. 1999;93:1858-1868.
9. Boccadoro M, Omede P, Dominietto A, et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant. 2000;25:25-29.
10. Martinelli G, Terragna C, Lemoli RM, et al. Clinical and molecular follow-up by amplification of the CDR-III IgH region in multiple myeloma patients after autologous transplantation of hematopoietic CD34 stem cells. Haematologica. 1999;84:397-404.
11. Comenzo RL, Wally J, Kica G, et al. Clonal immunoglobulin light chain vadable region germline gene use in AL amyloidosis: association with dominant amyloid-related organ involvement and survival after stem cell transplantation. Br J Haematol. 1999;106:744-751.
12. Willems P, Verhagen O, Segeren C, et al. Consensus strategy to quantitate malignant cells in myeloma patients is validated in a multicenter study. Blood. 2000;96:63-70.
13. Cremer FW, Kiel K, Wallmeier M, Goldschmidt H, Moos M. A quantitative PCR assay for the detection of low amounts of malignant cells in multiple myeloma. Ann Oncol. 1997;8:633-636.
14. Comenzo RL, Costello S, Reich L, et al. Results of autologous stem cell transplantation (SCT) following stem cell mobilization with melphalan in myeloma patients [abstract]. Blood. 2002;100:435a.
15. Moskowitz CH, Stiff P, Gordon MS, et al. Recombinant methionyl human stem cell factor and filgrastim for peripheral blood progenitor cell mobilization and transplantation in non-Hodgkin's lymphoma patients - results of a phase I/II trial. Blood. 1997;89:3136-3147.
16. L germline gene use and plasma cell burden. Blood. 2001;98:714-720.
17. Cremer FW, Kiel K, Wallmeier M, Haas R, Goldschmidt H, Moos M. Leukapheresis products in multiple myeloma: lower tumor load after mobilization with cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) compared with G-CSF alone. Exp Hematol, 1998;26:969-975.
18. Kiel K, Cremer FW, Ehrbrecht E, et al. First and second apheresis in patients with multiple myeloma: no differences in tumor load and hematopoietic stem cell yield. Bone Marrow Transplant. 1998;21:1109-1115.
19. Cremer FW, Ehrbrecht E, Kiel K, et al. Evaluation of the kinetics of the bone marrow tumor load in the course of sequential high-dose therapy assessed by quantitative PCR as a predictive parameter in patients with multiple myeloma. Bone Marrow Transplant. 2000;26:851-858.
20. Comenzo RL, Michelle D, LeBlanc M, et al. Mobilized CD34+ cells selected as autografts in patients with primary light-chain amyloidosis: rationale and application. Transfusion. 1998;38:60-69.
21. H gene sequences reveal a complementary imprint of antigen selection in tumor cells. Blood. 1997;89:219-226.
22. Kosmas C, Viniou N-A, Stamatopoulos K, et al. Analysis of the light chain variable region in multiple myeloma. Br J Haematol. 1996;94:306-317.
23. Sendak R, Wang F, Geagan L, et al. Comparison of two in vitro methods for the measurement of recombinant human TSH bioactivity. Biologicals. 2002;30:245-248.
24. Nauck MS, Nauck MA, Nauck MA, Marz W, Wieland H. Six methods for the determination of C-peptide evaluated. Clin Chem Lab Med. 1999;37:745-751.
25. Brenner M, Krance R, Heslop HE, et al. Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission. Hum Gene Ther. 1994;5:481-499.